Infection Prophylaxis in Myeloma Patients Receiving Bispecific Antibodies Therapies

Authored by Samer Al Hadidi, published on 2026-07-26 19:44:49.0

  1. Infection prophylaxis
    Important to be part of initial planning and treatment
    • Throughout treatment
    • During neutropenia
  2. Antiviral (VZV/HSV)
    Until 3-6 months post-BsAb
  3. Antibacterial
    Highest risk early cycles Consider G-CSF support
  4. Hypogammaglobulinemia
    IVIG until IgG greater than 400 (preferably regardless of level)
  5. Antifungal
    Overall risk is low (limit use to prolonged neutropenia)
  6. Pneumocystis (PJP)
    TMP-SMX until CD4 greater than 200 (or while on treatment)
  7. CMV and hepatitis B
    Entecavir if HBV risk
tosprivacy